TerminatedPhase 3

Alfuzosin Versus Placebo in Acute Urinary Retention

Stopped: The study was early terminated due to slow and difficult recruitment

Denmark160 participantsStarted 2004-05

Plain-language summary

The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization. Furthermore is investigated the safety of the medical treatment and self-catheterization.

Who can participate

Age range50 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men with acute urinary retention and catheterized * Benign hypertrophia of prostate * Patient is diagnosed in Emergency room or at a acute hospitalization Exclusion Criteria: * Known prostate cancer * Prior urinary retention within 30 days * Urinary retention occurring in relation to surgery * Blood in urine * Difficult or impossible catheterization * Fever \> 38 degree Celsius * Decreased kidney function * Permanent catheter \> 14 days * Treatment with alfa 1 blocker within 30 days * Meeting contraindications to treatment with Alfuzosin * Treatment with other drugs for urinary problems The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.

What they're measuring

Number of patients with satisfying spontaneous voiding after 14 days measured by bladder scan at day 14.

Trial details

NCT IDNCT00453908

SponsorSanofi

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Urinary Retention trials